Kenneth Abramowitz

Portfolio · 1

Entera Bio

Oral Delivery of Therapeutic Proteins

1 round $5.0M committed Latest: 2014-02

Investment activity

1 portfolio exit on record.

Q&A

What is Kenneth Abramowitz's primary investment focus by sector?

Kenneth Abramowitz primarily focuses on the Health Tech & Life Sciences sector, with one recorded investment and one exit in this area.

Has Kenneth Abramowitz had any notable exits?

Yes, Kenneth Abramowitz had an exit in July 2018 when portfolio company Entera Bio went public on NASDAQ with a valuation of $91M, having raised $11M in capital.

What is Kenneth Abramowitz's most notable portfolio company?

Kenneth Abramowitz's most notable portfolio company is Entera Bio, which specializes in the oral delivery of therapeutic proteins and went public in July 2018.

What is Kenneth Abramowitz's investment stage preference?

Kenneth Abramowitz has participated in Seed stage investments, with one recorded instance.

When was Kenneth Abramowitz's most recent investment activity?

Kenneth Abramowitz's most recent recorded investment activity was in February 2014.